Identification of novel mutations and functional impacts of EPAS1 in colorectal cancer

Abstract Endothelial PAS domain‐containing protein 1 (EPAS1) has implications in many cancers. However, the molecular behaviours, functional roles and mutational status of EPAS1 have never been studied in colorectal carcinoma (CRC). The study aims to examine the genetic alterations and functional ro...

Full description

Bibliographic Details
Main Authors: Farhadul Islam, Vinod Gopalan, Cu Tai Lu, Suja Pillai, Alfred K. Lam
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.4116
id doaj-2a4d6de5b44c4999935ab948192ae660
record_format Article
spelling doaj-2a4d6de5b44c4999935ab948192ae6602021-08-16T11:21:36ZengWileyCancer Medicine2045-76342021-08-0110165557557310.1002/cam4.4116Identification of novel mutations and functional impacts of EPAS1 in colorectal cancerFarhadul Islam0Vinod Gopalan1Cu Tai Lu2Suja Pillai3Alfred K. Lam4School of Biomedical Sciences Faculty of Medicine University of Queensland Brisbane Queensland AustraliaSchool of Medicine and Dentistry Griffith University Gold Coast Queensland AustraliaDepartment of Surgery Gold Coast University Hospital Southport Queensland AustraliaSchool of Biomedical Sciences Faculty of Medicine University of Queensland Brisbane Queensland AustraliaSchool of Biomedical Sciences Faculty of Medicine University of Queensland Brisbane Queensland AustraliaAbstract Endothelial PAS domain‐containing protein 1 (EPAS1) has implications in many cancers. However, the molecular behaviours, functional roles and mutational status of EPAS1 have never been studied in colorectal carcinoma (CRC). The study aims to examine the genetic alterations and functional roles of EPAS1 in CRC. In addition, the clinical impacts of EPAS1 in CRC were studied. Significant EPAS1 DNA amplification (63.4%; n = 52/82) and consequent mRNA overexpression (72%; n = 59/82) were noted in patients with CRC. In CRC, 16% (n = 13/82) of the patients had mutations in the EPAS1 coding sequence and most of the mutated samples exhibited aberrant DNA changes and mRNA overexpression. We have identified two novel variants, c.1084C>T; p.L362L and c.1121T>G; p.F374C in CRC. These EPAS1 aberrations in CRC were correlated with clinicopathological parameters, including tumour size, histological grade, T‐stages, cancer perforation as well as the presence of synchronous cancer. Also, reduced cell proliferation, wound healing, migration and invasion were noted in colon cancer cells followed by EPAS1 silencing. To conclude, the results obtained from the current study indicated that EPAS1 plays important role in colorectal carcinogenesis, thus, could be useful as a prognostic marker and as a target for therapy development.https://doi.org/10.1002/cam4.4116cancer geneticscancer prognosiscell proliferationcolorectal cancerEPAS1invasion
collection DOAJ
language English
format Article
sources DOAJ
author Farhadul Islam
Vinod Gopalan
Cu Tai Lu
Suja Pillai
Alfred K. Lam
spellingShingle Farhadul Islam
Vinod Gopalan
Cu Tai Lu
Suja Pillai
Alfred K. Lam
Identification of novel mutations and functional impacts of EPAS1 in colorectal cancer
Cancer Medicine
cancer genetics
cancer prognosis
cell proliferation
colorectal cancer
EPAS1
invasion
author_facet Farhadul Islam
Vinod Gopalan
Cu Tai Lu
Suja Pillai
Alfred K. Lam
author_sort Farhadul Islam
title Identification of novel mutations and functional impacts of EPAS1 in colorectal cancer
title_short Identification of novel mutations and functional impacts of EPAS1 in colorectal cancer
title_full Identification of novel mutations and functional impacts of EPAS1 in colorectal cancer
title_fullStr Identification of novel mutations and functional impacts of EPAS1 in colorectal cancer
title_full_unstemmed Identification of novel mutations and functional impacts of EPAS1 in colorectal cancer
title_sort identification of novel mutations and functional impacts of epas1 in colorectal cancer
publisher Wiley
series Cancer Medicine
issn 2045-7634
publishDate 2021-08-01
description Abstract Endothelial PAS domain‐containing protein 1 (EPAS1) has implications in many cancers. However, the molecular behaviours, functional roles and mutational status of EPAS1 have never been studied in colorectal carcinoma (CRC). The study aims to examine the genetic alterations and functional roles of EPAS1 in CRC. In addition, the clinical impacts of EPAS1 in CRC were studied. Significant EPAS1 DNA amplification (63.4%; n = 52/82) and consequent mRNA overexpression (72%; n = 59/82) were noted in patients with CRC. In CRC, 16% (n = 13/82) of the patients had mutations in the EPAS1 coding sequence and most of the mutated samples exhibited aberrant DNA changes and mRNA overexpression. We have identified two novel variants, c.1084C>T; p.L362L and c.1121T>G; p.F374C in CRC. These EPAS1 aberrations in CRC were correlated with clinicopathological parameters, including tumour size, histological grade, T‐stages, cancer perforation as well as the presence of synchronous cancer. Also, reduced cell proliferation, wound healing, migration and invasion were noted in colon cancer cells followed by EPAS1 silencing. To conclude, the results obtained from the current study indicated that EPAS1 plays important role in colorectal carcinogenesis, thus, could be useful as a prognostic marker and as a target for therapy development.
topic cancer genetics
cancer prognosis
cell proliferation
colorectal cancer
EPAS1
invasion
url https://doi.org/10.1002/cam4.4116
work_keys_str_mv AT farhadulislam identificationofnovelmutationsandfunctionalimpactsofepas1incolorectalcancer
AT vinodgopalan identificationofnovelmutationsandfunctionalimpactsofepas1incolorectalcancer
AT cutailu identificationofnovelmutationsandfunctionalimpactsofepas1incolorectalcancer
AT sujapillai identificationofnovelmutationsandfunctionalimpactsofepas1incolorectalcancer
AT alfredklam identificationofnovelmutationsandfunctionalimpactsofepas1incolorectalcancer
_version_ 1721205746070192128